Skip to main content

Every year, Mintz provides analysis of the regulatory developments that impact public companies as they prepare for their fiscal year-end filings with the Securities and Exchange Commission and their annual shareholder meetings. This memorandum discusses key considerations to keep in mind as you embark upon the year-end reporting process in 2025.

Although the SEC was not as active in adopting new rules in 2024 as the previous few years, this year public companies should continue to refine their disclosures and year-end process to address the SEC’s earlier rule making activities. In particular, companies need to be aware of the developing landscape of cybersecurity disclosures and the required disclosure of insider trading policies and option awards made close in time to the release of material non-public information. Additionally, companies need to assess the impact artificial intelligence may have on their business and review their AI disclosures carefully and continue to update their Environmental, Social, and Governance practices and disclosures.

In addition to summarizing these considerations, we address several other significant developments and considerations companies should focus on this year, including the need to thoughtfully review and refine risk factors and Management’s Discussion and Analysis of Financial Condition. We also provide an update on noteworthy U.S. Food and Drug Administration regulatory developments and recent litigation impacting corporate governance and disclosure.

Subscribe To Viewpoints

Authors

Anne L. Bruno is a Member at Mintz who advises clients ranging from start-ups to multinational public companies on issues related to corporate and employment law, including executive compensation, employee benefits, securities law, and corporate governance. She is also a key member of the firm’s multidisciplinary ESG practice, helping corporate boards, companies, and their investors navigate a broad range of environmental, social, and governance considerations.
Dan is a corporate and securities attorney whose practice spans the full gamut of corporate law. He has advised clients for over two decades in public and private equity and debt financings, securities law matters, mergers and acquisitions, and strategic advice on a broad range of other corporate matters. He capably counsels public and private companies with offerings, compliance, and securities questions and leads buyers and sellers throughout the transaction process. Dan represents life sciences companies as well as clients in other technology fields, financial services, and professional services firms.
Melanie Ruthrauff Levy is a Mintz attorney who counsels venture and private equity funds and public and private companies in corporate governance, public company reporting, and transactional matters. She represents issuers and financing sources in the life sciences, health care, and tech fields.

Page R. Hubben

Special Counsel

Page R. Hubben is a Mintz attorney who advises public companies on capital-raising transactions, SEC reporting, and corporate governance. She also counsels public and private companies on a broad range of executive compensation and equity compensation arrangements and programs, including equity and incentive plans and related tax, corporate, and securities law concerns.
David G. Adams is a securities regulatory and enforcement attorney with 20 years of experience in the financial services industry. He partners with innovators around the world to help them capitalize on emerging US legal and regulatory trends at the intersection of financial technology and US financial regulation.
Joanne counsels global clients on the regulatory and distribution-related implications when bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized.
Jacob H. Hupart is Co-Chair of the ESG Practice Group and a Member in the firm’s Litigation Section. He has a multifaceted litigation practice that encompasses complex commercial litigation, securities litigation — including class action claims — as well as white collar criminal defense and regulatory investigations. His clients sit in a variety of industries, including energy, financial services, education, health care, and the media.

Cynthia J. Larose

Member / Co-Chair, Privacy & Cybersecurity Practice

Cynthia J. Larose is Chair of the firm's Privacy & Cybersecurity Practice, a Certified Information Privacy Professional-US (CIPP-US), and a Certified Information Privacy Professional-Europe (CIPP-E). She works with clients in various industries to develop comprehensive information security programs on the front end, and provides timely counsel when it becomes necessary to respond to a data breach.
Breton Leone-Quick is an attorney who advises Mintz clients in the financial services industry in litigation matters and regulatory investigations. He leverages his understanding of federal securities laws and Delaware corporate laws to navigate complex crises and disputes.
Benjamin advises pharmaceutical, medical device and biotech companies on the FDA regulatory process to identify the correct regulatory pathway, assisting with FDA communications and strategy.
Christopher J. Buontempo is a Mintz corporate attorney and a Certified Information Privacy Professional (CIPP). He has significant experience handling issues relating to technology, data privacy and security, brand protection, contract negotiation, licensing, and product development.